Nothing Special   »   [go: up one dir, main page]

MX2020006650A - Esketamina para el tratamiento de la depresión. - Google Patents

Esketamina para el tratamiento de la depresión.

Info

Publication number
MX2020006650A
MX2020006650A MX2020006650A MX2020006650A MX2020006650A MX 2020006650 A MX2020006650 A MX 2020006650A MX 2020006650 A MX2020006650 A MX 2020006650A MX 2020006650 A MX2020006650 A MX 2020006650A MX 2020006650 A MX2020006650 A MX 2020006650A
Authority
MX
Mexico
Prior art keywords
depression
esketamine
treatment
patient
effective amount
Prior art date
Application number
MX2020006650A
Other languages
English (en)
Inventor
Jaskaran Singh
Ella Daly
Carla Canuso
Wayne Drevets
Honglan Li
David Wood Hough
Adam Janik
Rachel Ochs-Ross
Ewa Wajs
Peter Zannikos
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MX2020006650A publication Critical patent/MX2020006650A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para mantener una remisión estable o respuesta estable lograda por un paciente con depresión después de la administración de una cantidad terapéuticamente eficaz de esketamina durante una fase de administración inicial, que comprende la administración continua de una cantidad terapéuticamente eficaz de esketamina por al menos cinco meses durante una fase de administración posterior; la presente invención también proporciona métodos para el tratamiento a largo plazo de la depresión en un paciente que comprende administrar al paciente que necesita el tratamiento una cantidad terapéuticamente eficaz clínicamente probada como segura y clínicamente probada como eficaz de esketamina durante al menos seis meses; en algunas modalidades, la depresión es trastorno depresivo mayor o depresión resistente al tratamiento.
MX2020006650A 2017-12-22 2018-12-18 Esketamina para el tratamiento de la depresión. MX2020006650A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762609504P 2017-12-22 2017-12-22
US201862663206P 2018-04-26 2018-04-26
US201862663219P 2018-04-26 2018-04-26
US201862667406P 2018-05-04 2018-05-04
US201862675846P 2018-05-24 2018-05-24
US201862755905P 2018-11-05 2018-11-05
PCT/US2018/066143 WO2019126108A1 (en) 2017-12-22 2018-12-18 Esketamine for the treatment of depression

Publications (1)

Publication Number Publication Date
MX2020006650A true MX2020006650A (es) 2020-11-06

Family

ID=65003585

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020006650A MX2020006650A (es) 2017-12-22 2018-12-18 Esketamina para el tratamiento de la depresión.
MX2023012450A MX2023012450A (es) 2017-12-22 2020-07-13 Esketamina para el tratamiento de la depresion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023012450A MX2023012450A (es) 2017-12-22 2020-07-13 Esketamina para el tratamiento de la depresion.

Country Status (16)

Country Link
US (2) US11707440B2 (es)
EP (1) EP3501542A1 (es)
JP (2) JP2021506924A (es)
KR (2) KR20240011237A (es)
CN (2) CN112423789A (es)
AU (2) AU2018282466A1 (es)
BR (1) BR112020012473A2 (es)
CA (1) CA3086478A1 (es)
IL (1) IL275482A (es)
JO (1) JOP20200156A1 (es)
MA (1) MA47719A (es)
MX (2) MX2020006650A (es)
PH (1) PH12020500555A1 (es)
SG (1) SG11202005896WA (es)
TW (2) TWI843711B (es)
WO (1) WO2019126108A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
WO2016044150A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
KR20240011237A (ko) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
AU2019352028A1 (en) 2018-10-05 2021-03-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
CN114126595A (zh) * 2019-03-05 2022-03-01 杨森制药公司 用于治疗抑郁症的艾司氯胺酮
US20220151955A1 (en) * 2019-08-05 2022-05-19 The Ketamine Research Foundation Ketamine for the treatment of postpartum symptoms and disorders
WO2021038500A2 (en) * 2019-08-28 2021-03-04 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of patients with major depressive disorder, including suicidality
CN115135363A (zh) * 2019-09-13 2022-09-30 杨森制药公司 艾司氯胺酮的鼻内施用
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regimen with escitamine for the treatment of clinical depression
EP4233060A1 (en) * 2020-10-22 2023-08-30 Tonix Pharmaceuticals Holding Corp. Randomization honoring methods to assess the significance of interventions on outcomes in disorders
WO2024201274A1 (en) * 2023-03-24 2024-10-03 Janssen Pharmaceutica Nv Esketamine for use in the treatment of depression

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10025A (en) 1853-09-20 Improvement in turbines
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
JP4173538B2 (ja) 1995-02-24 2008-10-29 スチュアート エル ウェグ 痛みの管理及び解毒のためのケタミンの点鼻及び点眼投与
WO1997007750A1 (en) 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
FR2739294B1 (fr) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
FR2764807B1 (fr) 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent
PT1113785E (pt) 1998-07-24 2005-08-31 Seo Hong Yoo Solucoes aquosas limpidas de acidos biliares
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
AU2001291159A1 (en) 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CA2506615A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
EP2526987A3 (en) 2005-06-01 2013-04-24 SHL Group AB Device for delivering medicament
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
WO2007111880A2 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
WO2007123945A2 (en) 2006-04-21 2007-11-01 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
RU2008150624A (ru) 2006-05-22 2010-06-27 Ванда Фармасьютиклз, Инк. (Us) Лечение депрессивных расстройств
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
WO2009131794A1 (en) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
US9073819B2 (en) 2011-06-30 2015-07-07 University Of South Florida Compositions, methods of use, and methods of treatment
CA2851619C (en) 2011-10-14 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of hydroxynorketamine, dehydronorketamine and other ketamine metabolites in the treatment of depression and neuropathic pain
AU2012340015B2 (en) 2011-11-14 2017-09-21 Alfasigma S.P.A. Assays for selecting a treatment regimen for a subject with depression and methods for treatment
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
MX2014010939A (es) * 2012-03-12 2014-11-13 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
EP2887930A4 (en) 2012-08-23 2016-03-23 Stuart L Weg ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
CN105377371A (zh) 2013-04-12 2016-03-02 西奈山伊坎医学院 创伤后应激障碍的治疗方法
WO2015031410A1 (en) 2013-08-26 2015-03-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (es) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas
ES2726223T3 (es) 2014-01-14 2019-10-02 Childrens Hospital Med Ct Composiciones que comprenden ketamina para el tratamiento de un trastorno del espectro autista
HUE051264T2 (hu) 2014-04-17 2021-03-01 Develco Pharma Schweiz Ag Ketamin orális dózisformája
AU2015257825B2 (en) 2014-05-04 2018-08-02 Firmenich Sa Flavored food and beverage products
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
MA40462A (fr) 2014-08-13 2017-06-21 Janssen Pharmaceutica Nv Méthode de traitement de la dépression
WO2016044150A1 (en) * 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
WO2016109427A1 (en) 2014-12-31 2016-07-07 Icahn School Of Medicine At Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
KR20240011237A (ko) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민

Also Published As

Publication number Publication date
BR112020012473A2 (pt) 2020-11-24
CA3086478A1 (en) 2019-06-27
MX2023012450A (es) 2023-10-31
US11707440B2 (en) 2023-07-25
JP2021506924A (ja) 2021-02-22
KR20200113197A (ko) 2020-10-06
RU2020123893A (ru) 2022-01-24
AU2018282466A1 (en) 2019-07-11
KR20240011237A (ko) 2024-01-25
US20210386688A1 (en) 2021-12-16
MA47719A (fr) 2020-01-15
EP3501542A1 (en) 2019-06-26
RU2020123893A3 (es) 2022-04-29
AU2024227438A1 (en) 2024-11-07
PH12020500555A1 (en) 2021-05-17
US20240000728A1 (en) 2024-01-04
WO2019126108A1 (en) 2019-06-27
JOP20200156A1 (ar) 2022-10-30
TW202415363A (zh) 2024-04-16
CN117531017A (zh) 2024-02-09
TW201940162A (zh) 2019-10-16
CN112423789A (zh) 2021-02-26
TWI843711B (zh) 2024-06-01
IL275482A (en) 2020-08-31
SG11202005896WA (en) 2020-07-29
JP2024001204A (ja) 2024-01-09

Similar Documents

Publication Publication Date Title
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2019012884A (es) Terapia de combinacion.
MX2022011334A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
MX2024010140A (es) Nuevos metodos.
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2022000143A (es) Metodos novedosos.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12017500392A1 (en) Medical treatments based on anamorelin
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
EA202193276A1 (ru) Способы лечения холангиокарциномы
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.
MX2016011002A (es) Tratamiento de angioedema hereditario con inhibidor c1.
UA111312C2 (uk) Спосіб лікування гострого коронарного синдрому без елевації сегмента st у пацієнтів з ішемічною хворобою серця та метаболічним синдромом, що перенесли перкутанну транслюмінарну коронарну ангіопластику
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
UA104030U (uk) Спосіб лікування хворих із загостренням хронічного бронхіту вірусної етіології
UA95104U (uk) Спосіб терапії хворих на негоспітальну пневмонію з супутньою хсн
MX2012012712A (es) Composicion farmaceutica para uso en el tratamiento o prevencion de una o varias enfermedaes inflamatorias y/o enfermedades autoinmunitarias.